Skip to main content
icon for Cyclosporiasis cases in U.S. by July 31?

Cyclosporiasis cases in U.S. by July 31?

icon for Cyclosporiasis cases in U.S. by July 31?

Cyclosporiasis cases in U.S. by July 31?

$21,849 Vol.

Jul 31, 2026
Polymarket

$21,849 Vol.

Polymarket

1800+

$2,616 Vol.

96%

2000+

$2,358 Vol.

95%

2500+

$3,757 Vol.

92%

3000+

$5,627 Vol.

77%

5000+

$2,763 Vol.

59%

10000+

$4,727 Vol.

5%

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.As of mid-July 2026, CDC surveillance shows the typical seasonal rise in cyclosporiasis cases driven by foodborne transmission of Cyclospora cayetanensis oocysts in contaminated fresh produce such as berries and leafy greens. Confirmed case counts remain consistent with historical summer patterns rather than indicating a large multistate outbreak, supporting trader focus on whether totals will exceed baseline thresholds by July 31. Key variables include import volumes, produce sourcing changes, and any new clusters identified through notifiable disease reporting. CDC's ongoing weekly or monthly updates on laboratory-confirmed cases will provide the next authoritative data releases that could shift market-implied odds.

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.

Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
Volume
$21,849
End Date
Jul 31, 2026
Market Opened
Jul 14, 2026, 9:55 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.As of mid-July 2026, CDC surveillance shows the typical seasonal rise in cyclosporiasis cases driven by foodborne transmission of Cyclospora cayetanensis oocysts in contaminated fresh produce such as berries and leafy greens. Confirmed case counts remain consistent with historical summer patterns rather than indicating a large multistate outbreak, supporting trader focus on whether totals will exceed baseline thresholds by July 31. Key variables include import volumes, produce sourcing changes, and any new clusters identified through notifiable disease reporting. CDC's ongoing weekly or monthly updates on laboratory-confirmed cases will provide the next authoritative data releases that could shift market-implied odds.

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.

Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
Volume
$21,849
End Date
Jul 31, 2026
Market Opened
Jul 14, 2026, 9:55 PM ET

Resolver

0x65070BE91...
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.

Related

icon for Will there be at least 2300 measles cases in the U.S. by July 31, 2026?

Will there be at least 2300 measles cases in the U.S. by July 31, 2026?

89%
icon for Will there be at least 3000 measles cases in the U.S. in 2026?

Will there be at least 3000 measles cases in the U.S. in 2026?

87%
icon for Will South Sudan have an Ebola case in 2026?

Will South Sudan have an Ebola case in 2026?

65%

Beware of external links.

Frequently Asked Questions

"Cyclosporiasis cases in U.S. by July 31?" is a prediction market on Polymarket with 6 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "1800+" at 96%, followed by "2000+" at 95%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 96¢ implies that the market collectively assigns a 96% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

As of today, "Cyclosporiasis cases in U.S. by July 31?" has generated $21.8K in total trading volume since the market launched on Jul 14, 2026. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.

To trade on "Cyclosporiasis cases in U.S. by July 31?," browse the 6 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current frontrunner for "Cyclosporiasis cases in U.S. by July 31?" is "1800+" at 96%, meaning the market assigns a 96% chance to that outcome. The next closest outcome is "2000+" at 95%. These odds update in real-time as traders buy and sell shares, so they reflect the latest collective view of what's most likely to happen. Check back frequently or bookmark this page to follow how the odds shift as new information emerges.

The resolution rules for "Cyclosporiasis cases in U.S. by July 31?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.